PCM
TMO icon

Prelude Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Prelude Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,900
Closed -$835K – 1746
2016
Q1 		$835K Buy
+5,900
New +$791K 0.12% 196

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Prelude Capital Management's TMO Position: Q2 2026 in Review

Prelude Capital Management increased its Thermo Fisher Scientific (TMO) stake by 588% in Q2 2026, buying an estimated $2.36M and bringing the position to 5,752 shares worth $2.88M. The position accounts for 0.21% of the portfolio, ranked #119.

Prelude Capital Management first reported a position in TMO in Q2 2013 and has held it in 33 quarters since. 2,630 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Prelude Capital Management held 5,752 shares of Thermo Fisher Scientific worth $2.88M as of Q2 2026.
  • Prelude Capital Management bought 4,916 Thermo Fisher Scientific shares in Q2 2026, an estimated $2.36M.
  • Thermo Fisher Scientific made up 0.21% of Prelude Capital Management's portfolio in Q2 2026, its #119 holding.
  • Prelude Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 33 quarters since.
  • 2,630 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.